MedTrace Logo

High Dose CVVHDF Compared to Standard Dose CVVHDF

NCT00561431 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-04-14

Study results available
· View outcomes & findings →

Summary

In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU has remained unchanged at greater than 50%, despite improvements in dialysis technology.

The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration (CVVHDF) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater reduction in all-cause ICU mortality compared to standard CVVHDF using an ultrafiltration rate of 20 ml/hr/kg.

Conditions

  • Acute Renal Failure

Interventions

DEVICE

Standard dose of dialysis

Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr

DEVICE

High dose of dialysis

Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Ashita J. Tolwani, MD · The University of Alabama at Birmingham, Division of Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561431 on ClinicalTrials.gov